Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81%
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note
ENLV
/
Balance Sheet
/
PP&E Net

Enlivex Therapeutics Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enlivex Therapeutics Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
PP&E Net
$2m
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
PP&E Net
$5.9m
CAGR 3-Years
6%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
PP&E Net
$43.6m
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
7%
Urogen Pharma Ltd
NASDAQ:URGN
PP&E Net
$1.7m
CAGR 3-Years
-21%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
PP&E Net
₪17m
CAGR 3-Years
113%
CAGR 5-Years
19%
CAGR 10-Years
28%
Pluri Inc
NASDAQ:PLUR
PP&E Net
$7.2m
CAGR 3-Years
61%
CAGR 5-Years
8%
CAGR 10-Years
-4%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Enlivex Therapeutics Ltd's PP&E Net?
PP&E Net
2m USD

Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's PP&E Net amounts to 2m USD.

What is Enlivex Therapeutics Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
11%

Over the last year, the PP&E Net growth was -86%. The average annual PP&E Net growth rates for Enlivex Therapeutics Ltd have been -4% over the past three years , 11% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.